CLAIMS

1. Compounds of formula (I)

cyclo[NX_1-R_1-CO-NX_2-R_2-CO-NX_3-R_3-CO-NX_4-R_4-CO-NX_5-R_5-CO]

where:

R_1 is selected from:

$CH(CH_2)_3NHC(NH)NH_2$; $C[CH_nF_m](CH_2)_3NHC(NH)NH_2$

R_2 is the group CH_2; CH_2-CH_2;



R_3 is selected from $CHCH_2COOH$; $C[CH_nF_m]CH_2$-COOH;

R_4 is selected from CH-CH_2-Ph; $C[CH_nF_m]CH_2$-Ph; CH-CH_2-(4-OH)Ph; CH-CH_2-(4-OMe)Ph; CH-CH_2-(4-F)Ph; CH-CH(OH)-Ph; $C(CH_3)_2$; CH-$C(CH3)_3$; CH-CH_2-COOH;



R_5 is selected from CH-CH_2-Ph; $C[CH_nF_m]CH_2$-Ph; CH-$CH(CH_3)_2$; $C[CH_nF_m]CH(CH_3)_2$; CH-$C(CH_3)_3$;

or, the group NX_4-R_4-CO-NX_5-R_5-CO is 3-aminomethyl-benzoyl

n + m = 3

X_1-X_5, which may be the same or different, are H, $(CH_2)_n$-CH_3;

-NX_4-R_4- =  ; 

$(CH_2)_n$-CHF_2; $(CH_2)_n$-CH_2F, $(CH_2)_n$-CF_3 where n = 0-3;

with the proviso that there is at least one α-fluoroalkylated amino acid present in the formula (I) compound;

where each NX-R-CO amino acid can have an absolute type R or type S configuration; their individual enantiomers, diastereoisomers, the related mixtures, the pharmaceutically acceptable salts.

2. Compound according to claim 1, selected from the group consisting of:

c(Arg-Gly-Asp-D-Phe-(*R or* S)-Tfm-Phe);
c(Arg-Gly-Asp-D-Phe-(*R*,S)-Dfm-Phe);
c(Arg-Gly-Asp-(*R or* S)-Tfm-Phe-Asp-D-Phe-Val);
c(Arg-Gly-Asp-(*R or* S)-Tfm-Phe-Val);
c(Arg-Gly-Asp-D-Phe-(*R or* S)-Tfm-Val)
c(Arg-Gly-Asp-D-Phe-(*R* or *S*)-N-Me-Tfm-Phe.

3. Use of the compounds according to claims 1 or 2 as medicaments.

4. Use of the compounds according to claims 1 or 2 for the preparation of medicaments that inhibit the receptors belonging to the family of the integrins belonging to the $\alpha_v\beta_3$ and $\alpha_v\beta_5$ system.

5. Use according to claim 4, where said medicaments have antiangiogenic activity.

6. Use according to claim 5, where said medicaments have antimetastatic activity.

7. Use according to claim 5, where said medicaments are useful for the treatment of a disease selected from the group consisting of retinopathy, acute kidney failure, and osteoporosis.

8. Pharmaceutical compositions containing at least one compound according to claims 1 or 2 as an active ingredient in a mixture with pharmaceutically acceptable vehicles and/or excipients.

9. Use of compounds according to claims 1-2 for the preparation of diagnostic agents.

10. Use according to claim 9, where said compound is labelled.

11. Use according to claims 9 or 10, where said diagnostic agent is used for the detection and location of tumour masses.

12. Use according to claim 11, where said tumour masses are small.

13. Use according to claims 9 or 10, where said diagnostic agent is used for detecting and locating arterial occlusion events.

14. Use according to claim 13, where said event is a stroke or myocardial infarct.

15. A diagnostic agent containing at least one compound according to claims 1 or 2.